Title: Belatacept
CAS Registry Number: 706808-37-9
CAS Name: [29-Tyrosine,104-glutamic acid] CTLA-4 (antigen) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment), bimol. (120®120¢)-disulfide
Additional Names: LEA29Y
Manufacturers' Codes: BMS-224818
Literature References: Selective costimulation blocker similar to abatacept, q.v. Soluble fusion protein combining a modified form of the extracellular portion of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with the constant region of human IgG1. Prepn: R. J. Peach et al., WO 0192337; eidem US 05214313 (2001, 2005 both to Bristol-Myers Squibb). Pharmacology and development: C. P. Larsen et al., Am. J. Transpl. 5, 443 (2005). Clinical trial in rheumatoid arthritis: L. W. Moreland et al., Arthritis Rheum. 46, 1470 (2002); in renal transplantation: F. Vincenti et al., N. Engl. J. Med. 353, 770 (2005).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.
Belladonna Belladonnine Bemegride Bemotrizinol Benactyzine

Clinical data
Trade names Nulojix
AHFS/ Consumer Drug Information
MedlinePlus a606016
Licence data US FDA:link
Pregnancy cat. C (US)
Legal status -only (US)
Routes Intravenous
ATC code L04AA28
Chemical data
Formula  ?
 N (what is this?)  (verify)

Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.[2]